Evidence map›Paper›PMID 34495311›Full record

ArticleBlood advances2021

Pretransplantation EASIX predicts intensive care unit admission in allogeneic hematopoietic cell transplantation.

Marta Peña, Maria Queralt Salas, Alberto Mussetti, Gabriel Moreno-Gonzalez, Anna Bosch, Beatriz Patiño, Laura Jiménez, Meriem Kara, Rocío Parody, Anna Sureda

Abstract read
In one paragraph

Article in Blood advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores.Hematology. American Society of Hematology. Education Program · 2023
    Article
  16. Article
  17. Preconditioning Modified-Easix as a Predictor of Prognosis in Allogeneic Hematopoietic Stem Cell Transplant Recipients.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2023
    Article
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marta PeñaClinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.ORCID 0000-0001-6601-7276
Maria Queralt SalasClinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.ORCID 0000-0003-4567-3682
Alberto MussettiClinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.ORCID 0000-0002-4088-036X
Gabriel Moreno-GonzalezIntensive Care Medicine, Bellvitge University Hospital, Barcelona, Spain; and.ORCID 0000-0003-3281-1126
Anna BoschClinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.ORCID 0000-0002-9147-3692
Beatriz PatiñoClinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.ORCID 0000-0002-5519-3888
Laura JiménezClinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.ORCID 0000-0002-1548-447X
Meriem KaraClinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.
Rocío ParodyClinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.ORCID 0000-0003-0375-7570
Anna SuredaClinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.ORCID 0000-0002-1238-6970

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Endothelial Activation and Stress Index (EASIX) is a laboratory-based prognosis index defined as creatinine × lactate dehydrogenase/platelets. When measured at pretransplantation evaluation (EASIX-PRE), it predicts allogeneic hematopoietic cell transplantation (alloHCT) mortality. This study explores its ability to predict intensive care unit (ICU) admission and validates EASIX-PRE predictive power for overall survival (OS) and nonrelapse mortality (NRM) in 167 consecutive patients undergoing alloHCT. EASIX-PRE was calculated retrospectively in all patients and transformed into log2 values (log2-EASIX-PRE). Log2-EASIX-PRE predicted ICU admission (hazard ratio [HR], 1.41; P < .001), OS (HR, 1.19; P = .011), and NRM (HR, 1.28; P = .004). The most discriminating EASIX-PRE cutoff value for risk of ICU admission was the 75th percentile (2.795); for OS and NRM, it was the median value (1.703). Patients with EASIX-PRE >2.795 had higher incidence of ICU admission in comparison with patients with lower EASIX-PRE values (day +180, 35.8% vs 12.8%; HR, 2.28; P = .010). Additionally, patients with EASIX-PRE >1.073 had lower OS (2 years, 57.7% vs 68.7%; HR, 1.98; P = .006) and higher NRM (2 years, 38.7% vs 18.5%; HR, 2.92; P = .001) than patients with lower EASIX-PRE results. Log2-EASIX-PRE was not associated with incidence of transplantation-associated microangiopathy, sinusoidal obstruction syndrome, or acute graft-versus-host disease. This study proposes EASIX-PRE as a prognostic tool to identify patients undergoing alloHCT at increased risk of severe organ dysfunction and who would therefore require ICU admission. Early identification of patients at high risk of severe events could contribute to personalized intervention design. Additionally, it validates the association between EASIX-PRE and OS and NRM in those undergoing alloHCT.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansIntensive Care UnitsRetrospective StudiesTransplantation, Homologous

Identifiers

PMID34495311
PMCPMC8525231

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.